Mindset BioPharmaceuticals

Mindset Pharma is a drug discovery and development company focused on creating optimized, next-generation psychedelic medicines for the treatment of neurological and psychiatric disorders. The company utilizes a proprietary drug discovery platform to design novel small molecules that aim to improve the safety, efficacy, and scalability of traditional psychedelic substances like psilocybin and DMT. Their lead candidate, MSP-1014, is a psilocybin analog being developed for treatment-resistant depression. In 2023, Mindset Pharma was acquired by Otsuka Pharmaceutical, integrating its innovative pipeline into Otsuka's broader CNS portfolio. The company continues to operate as a subsidiary, leveraging its expertise in structure-based drug design to address unmet needs in mental health.